molecular simulations that shape the future of computational science
InterX, Inc. is a biotechnology startup revolutionizing biomolecular computation. Our goal is to achieve robust and accurate prediction of molecular and ensemble properties of biological systems. Led by Nobel Prize-winning scientists, InterX is creating tools for pharmaceutical ligand design, material science, and biochemistry.
precision of ensemble properties
prediction for Ligand binding
What We Do
Using principles of Physics, Mathematics, Computer Science, and Computational Chemistry and Biology, InterX derives rules of molecular interactions to predict the properties and behaviors of complex systems. Through advanced proprietary software that approximates inherently quantum mechanical processes underlying biochemical interactions, InterX develops novel and reliable means of predicting the real-world outcomes of biophysical processes.
innovations rooted in collaborative research
InterX is located in Berkeley, California and operates at the nexus of academic research and pharma-tech industry. We partner with leading edge researchers, drug developers, and biotechnology companies across the globe to predict drug-target interactions using the most advanced computer algorithms available.
research collaborators and organizations
Voronina Ekaterina Nikolaevna, Ph.D., Lomonosov Moscow State University
Maria Kurnikova, Ph.D., Associate Professor, Chemistry, Carnegie Mellon University
The InterX team is an international group of physicists, mathematicians, chemists, biologists, and software engineers who are passionate about making an enduring contribution to science. We are looking for exceptional individuals who want to be a part of cutting-edge physics and biophysics research.